(0.18%) 5 317.73 points
(0.21%) 39 991 points
(0.15%) 16 767 points
(0.59%) $79.09
(2.81%) $2.48
(-0.33%) $2 387.00
(0.69%) $29.94
(-0.25%) $1 067.40
(0.13%) $0.920
(0.29%) $10.70
(0.09%) $0.789
(0.16%) $90.83
@ $0.697
Issued: 14 Feb 2024 @ 09:37
Return: 20.50%
Previous signal: Feb 12 - 14:32
Previous signal:
Return: 4.84 %
Live Chart Being Loaded With Signals
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform...
Stats | |
---|---|
Today's Volume | 470 069 |
Average Volume | 803 006 |
Market Cap | 81.11M |
EPS | $0 ( 2024-05-09 ) |
Next earnings date | ( $-0.100 ) 2024-06-17 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.750 |
ATR14 | $0.00800 (0.95%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Orlinger Klaus | Buy | 367 300 | Stock Option (Right to Buy) |
2024-04-15 | Aldag Jorn | Buy | 971 400 | Stock Option (Right to Buy) |
2024-04-15 | Winderlich Mark | Buy | 250 000 | Stock Option (Right to Buy) |
2024-04-15 | Winderlich Mark | Buy | 50 000 | Stock Option (Right to Buy) |
2024-04-15 | Kandera Reinhard | Buy | 406 200 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
98.83 |
Last 94 transactions |
Buy: 7 455 375 | Sell: 565 370 |
Volume Correlation
HOOKIPA Pharma Inc Correlation
10 Most Positive Correlations | |
---|---|
TCRT | 0.916 |
VSTA | 0.914 |
JNCE | 0.904 |
INFI | 0.903 |
MPAA | 0.903 |
VCSA | 0.902 |
POWW | 0.899 |
VIRX | 0.899 |
GRAY | 0.897 |
TOI | 0.896 |
10 Most Negative Correlations | |
---|---|
IMMR | -0.897 |
PBFS | -0.892 |
BNIXU | -0.887 |
ISIG | -0.875 |
WEN | -0.873 |
CCRC | -0.872 |
MGI | -0.869 |
SEDG | -0.864 |
IBEX | -0.862 |
MSON | -0.859 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
HOOKIPA Pharma Inc Correlation - Currency/Commodity
HOOKIPA Pharma Inc Financials
Annual | 2023 |
Revenue: | $20.13M |
Gross Profit: | $16.58M (82.35 %) |
EPS: | $-0.860 |
FY | 2023 |
Revenue: | $20.13M |
Gross Profit: | $16.58M (82.35 %) |
EPS: | $-0.860 |
FY | 2022 |
Revenue: | $14.25M |
Gross Profit: | $10.65M (74.72 %) |
EPS: | $-0.990 |
FY | 2021 |
Revenue: | $18.45M |
Gross Profit: | $18.45M (100.00 %) |
EPS: | $-2.79 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
HOOKIPA Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators